Sr. Research Scientist - CNS Neurology Endpoints
Apellis Pharmaceuticals, Inc. | |
life insurance, paid time off, 401(k) | |
United States, Massachusetts, Waltham | |
100 5th Avenue (Show on map) | |
Nov 17, 2024 | |
Position Summary: The Sr. Translational Research Scientist is accountable for the identification and translational endpoint strategy for CNS Neurology projects. Specifically, the employee will be responsible for developing cross-functional program-level strategies to identify novel fluid, digital, imaging, and/or technology-related endpoints for use in preclinical and early-stage clinical neurology programs, enabling conclusive and efficient go/no go decisions and/or patient stratification strategies. The role will entail demonstrating proof of concept for potential endpoints in nonclinical in-vitro, ex-vivo or in-vivo studies; evaluating new endpoints or patient stratification strategies using available clinical data sets and/or patient samples; identification and collaboration with academics and companies to gain access to endpoint technologies; and implementation in clinical studies via cross functional collaboration within CNS Neurology program teams as well as the Clinical Pharmacology and Translational Clinical Development functions. The successful candidate will interface within the research, clinical and program teams to provide scientific expertise to guide strategic decision making for existing and future CNS and neurology programs. The position will report to the Head of Research. Key Responsibilities Include:
Education, Registration & Certification:
Experience:
Physical Demands and Work Environment:
Travel Requirements:
Benefits and Perks: Apellis offers a great benefit package which includes: health insurance with full premium coverage, 401K with company match, paid time off (PTO), long- term disability insurance, life insurance and more! Visit https://apellis.com/careers/ to learn more. Company Background: Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn EEO Statement: Apellis is an equal opportunity employer and complies with all applicable federal, state and local fair employment practices laws. Apellis strictly prohibits and does not tolerate discrimination against employees, applicants or any other covered persons because of race, color, religion, creed, national origin or ancestry, ethnicity, sex (including pregnancy), gender (including gender nonconformity and status as a transgender or transsexual individual), age, physical or mental disability, citizenship, past, current or prospective service in the uniformed services, genetic information, marital status, AIDS/HIV status, smoker/nonsmoker, and occupational pneumoconiosis or any other characteristic protected under applicable federal, state or local law. For San Francisco postings: Pursuant to the San Francisco Fair Chance Ordinance, we will consider for employment qualified applicants with arrest and conviction records. Other Duties: Please note this job description is not designed to cover or contain a comprehensive listing of activities, duties or responsibilities that are required of the employee for this job. Duties, responsibilities and activities may change at any time with or without notice. |